News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Amol Akhade: Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO.
Photo taken from Amol Akhade/Twitter
Oct 21, 2023, 19:37

Amol Akhade: Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO.

Amol Akhade, Senior Consultant in Medical and Hematooncology at the Dr Hitendra Patil’s Suyog Cancer Clinics, Thane, shared on X/Twitter an insight from ESMO23:

“Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO. We have better questions to answer. Like IO resistance. Let’s use our resources better.”

Source: Amol Akhade/Twitter.

Amol Akhade cancer ESMO23 OncoDaily Oncology pembrolizumab
Special Coverage
Dialogues
Aug 8, 2025, 06:16
Accelerating Cancer Drug Development with AI: Interview with Dr. Jen-Tang (JT) Lu from Vysioneer
Blog
Aug 8, 2025, 06:08
Better-Targeted Therapies for Patients with Acute Myeloid Leukemia - IU Simon Comprehensive Cancer Center
Blog
Aug 8, 2025, 05:59
The Silver Jubilee of the Townsville to Cairns Bike Ride: Raising Funds for Childhood Cancer - Children's Cancer Institute
Insight
Aug 8, 2025, 05:47
FASCO 2025: 97 Voices, One Mission: Part 2
Science
Aug 8, 2025, 05:44
Yan Leyfman: Turning Paradoxical Biology Into Precision Immunotherapy Opportunities
Science
Aug 8, 2025, 05:01
Arndt Vogel: ESMO-MCBS 2.0 Scorecards for Hepatocellular Carcinoma
Oncolibrary
Aug 8, 2025, 03:13
CAR T-Cell Therapy vs iNKT Cell Therapy: The Future of Engineered Immune Cells in Cancer Treatment
Oncolibrary
Aug 8, 2025, 03:09
Immunotherapy for Cancer Success Rate: What Patients Need to Know in 2025
Oncolibrary
Aug 8, 2025, 01:07
10-Minute Immunotherapy Infusion: Safe, Efficient Delivery of Nivolumab and Pembrolizumab
Societies
Aug 7, 2025, 23:50
Because Every Patient Matters: Promoting Diversity in Cancer Support - MASCC
Blog
Aug 7, 2025, 22:17
Arif Kamal: ACS is Celebrating 60 Years of Community-Driven Primary Care at Health Centers
Blog
Aug 7, 2025, 21:48
Michael Ziener: NFL and ACS Join Forces to Expand Cancer Screening Access